A new study has identified a life-and-death signaling role for a molecule on the surface of the...
Although cancer recurrence may be the overriding fear for many survivors, nearly half of...
New research points to an intimate relationship between mast cells—immune system cells that are...
Recent meetings have provided a showcase for many potential druggable tumor targets. The range of potential new drug targets has been expansive, especially if one counts the whole-exome sequencing work being performed for the Cancer Genome Atlas project.
The day-to-day pressures on a compound manager come from several directions. There is pressure to support the increasing demands for samples in more diverse delivery formats; pressure to keep operational and supply costs down; and there has been the unfortunate trend toward staff reductions.
Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease are common killers worldwide. Now, researchers have described the molecular pathway responsible for excess mucus in airway cells and have used that information to design a series of new drugs that inhibit that pathway.
A study that reveals new understanding of molecular changes that convert harmless cells surrounding ovarian cancer cells into cells that promote tumor growth and metastasis can provide potential new therapeutic targets for this deadly disease.
Trauma in infancy and childhood shapes the brain, learning, and behavior, and fuels changes that can last a lifetime, according to new human and animal research. The studies delve into the effects of early physical abuse, socioeconomic status (SES), and maternal treatment.
New findings report the important role sleep plays, and the brain mechanisms at work as sleep shapes memory, learning, and behavior. The findings were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience in New Orleans.
Studies exploring the neurological component of dietary disorders uncovered evidence that the brain’s biological mechanisms may contribute to significant public health challenges—obesity, diabetes, binge eating, and the allure of the high-calorie meal. The findings were presented at Neuroscience 2012.
Berkeley Lab scientists have identified tissue mechanisms that may influence a woman’s susceptibility or resistance to breast cancer after exposure to low-dose ionizing radiation, such as the levels used in full-body CT scans and radiotherapy. The research could lead to new ways to identify women who have higher or lower risks of breast cancer from low-dose radiation.
New findings in medical imaging, molecular analysis of neurological diseases, and development of treatments using mouse models are helping researchers develop early, accurate diagnostic tests and treatments for Alzheimer's disease, the most common cause of dementia.
New animal studies provide additional support for investigating stem cell treatments for Parkinson’s disease, head trauma, and dangerous heart problems that accompany spinal cord injury, according to research findings released at Neuroscience 2012.
All biological specimens are three-dimensional. A greater understanding of the structure-function relationship in cells and tissues is now within reach through high-resolution correlation of chemical markers and structural components in three dimensions.
Electron microscopes are thousands of times more powerful than light microscopes, capable of visualizing single atoms and detecting differences in their positions as small as 50 picometers. Unfortunately, most biological specimens share characteristics that pose challenges to scientists’ ability to realize EM’s full potential.
Low-energy electrons interact much more strongly with the sample than the high-energy electrons from classical transmission electron microscopes. Electrons in the LVEM5 are strongly scattered by organic materials resulting in strong differentiation of features.
Stem cells offer unique opportunities for researchers to study the reaction of drugs applied to human tissues. Moreover, stem cells can model healthy or diseased states, as well as provide the ability to genetically modify cells before drug treatment.
Two research groups are using Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes, and metabolic disease.
After a quick nod to the laborious ways of the old, let us ring in the new innovations in multiplex assays with what is quite literally, a new ring.
New research shows a sharp escalation in the weapons race against cancer, with several high-tech approaches long dreamed of but not possible or successful until now.
Onconova Therapeutics Inc. announced updates regarding the development of an oral formulation of rigosertib (Estybon, ON 01910.Na) for patients with solid tumors and myelodysplastic syndromes.
Opportunities exist for pharmaceutical companies to increase their offerings in the traumatic brain injury (TBI) market, as current therapeutic options for TBI patients are not efficient enough to greatly reduce mortality or prevent brain damage.
AVEO Oncology and Astellas Pharma Inc. will present detailed data from TIVO-1 (Tivozanib Versus Sorafenib in first line Advanced RCC) at the 2012 Annual Meeting of the American Society of Clinical Oncology.
Bristol-Myers Squibb Co. will announce new data on its approved and investigational oncology compounds at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) from June 1-5.
In order to foster innovation, reduce costs, and halt the erosion of revenue, major pharmaceutical companies are exploring a range of new and emerging research arrangements.
Compounds found in curry are being investigated as a way of improving drug response in patients with advanced bowel cancer in a new study.
The first randomized controlled trial to assess the effectiveness of memantine, a drug prescribed for Alzheimer's disease, showed the drug does not ease clinically significant agitation in patients.
The Accelerated Cure Project for Multiple Sclerosis and the MassGeneral Institute for Neurodegenerative Disease launched the Multiple Sclerosis Discovery Forum, an interactive virtual community and information portal that connects and educates investigators who study MS and other demyelinating disorders of the central nervous system.